In March 2017, the US Food and Drug Administration (FDA) granted accelerated approval to<unk>  for the treatment of adults and children twelve years and older with metastatic Merkel-cell carcinoma (MCC). In May 2017, the FDA approved<unk>  for people with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within twelve months of neoadjuvant or adjuvant platinum-containing chemotherapy. In May 2019, the FDA approved<unk>  in combination with axitinib for the first-line treatment of people with advanced renal cell carcinoma. In June 2020, the FDA approved<unk>  for the maintenance treatment of people with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Avelumab
Alirocumab
Emapalumab
Anifrolumab
Burosumab
Evolocumab
Secukinumab
Olaratumab